Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias. Musto P, et al. Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894. Cancer. 2010. PMID: 20151429 Free article.
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, Niscola P, Naso V, Nobile C, Piccioni AL, D'Andrea M, D'Addosio A, Leone G, Venditti A. Voso MT, et al. J Clin Oncol. 2013 Jul 20;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764. Epub 2013 Jun 24. J Clin Oncol. 2013. PMID: 23796988
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A. Maurillo L, et al. Among authors: voso mt. Eur J Haematol. 2015 Jul;95(1):52-6. doi: 10.1111/ejh.12476. Epub 2015 Mar 12. Eur J Haematol. 2015. PMID: 25764148
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Voso MT, Niscola P, Piciocchi A, Fianchi L, Maurillo L, Musto P, Pagano L, Mansueto G, Criscuolo M, Aloe-Spiriti MA, Buccisano F, Venditti A, Tendas A, Piccioni AL, Zini G, Latagliata R, Filardi N, Fragasso A, Fenu S, Breccia M; GROM (Gruppo Romano e Laziale MDS) and Basilicata MDS Registry. Voso MT, et al. Eur J Haematol. 2016 Apr;96(4):344-51. doi: 10.1111/ejh.12595. Epub 2015 Jun 21. Eur J Haematol. 2016. PMID: 26018238
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.
Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F. Amadori S, et al. Among authors: voso mt. J Clin Oncol. 2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811524 Free article. Clinical Trial.
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
Buccisano F, Piccioni AL, Nobile C, Criscuolo M, Niscola P, Tatarelli C, Fianchi L, Villivà N, Neri B, Carmosino I, Gumenyuk S, Mancini S, Voso MT, Maurillo L, Breccia M, Zini G, Venditti A, Fenu S, Spiriti MA, Latagliata R; GROM (Gruppo Romano Mielodisplasie). Buccisano F, et al. Among authors: voso mt. Ann Hematol. 2016 Jun;95(7):1059-65. doi: 10.1007/s00277-016-2667-1. Epub 2016 Apr 19. Ann Hematol. 2016. PMID: 27091349
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A, Avvisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco F. Cicconi L, et al. Among authors: voso mt. Leukemia. 2016 Oct;30(10):1987-1992. doi: 10.1038/leu.2016.122. Epub 2016 May 2. Leukemia. 2016. PMID: 27133819 Clinical Trial.
Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F, Voso MT, Hohaus S, Gentile M, Vigna E, Recchia AG, Iovino L, Benedetti E, Lo-Coco F, Galimberti S. Morabito F, et al. Among authors: voso mt. Expert Opin Investig Drugs. 2016 Sep;25(9):1117-31. doi: 10.1080/13543784.2016.1216971. Epub 2016 Aug 8. Expert Opin Investig Drugs. 2016. PMID: 27485472 Review.
305 results